Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

摘要: Background. Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders. The associated long-term risks of infection remain poorly defined. Methods. From July 2001 through December 2003, all patients who received alemtuzumab the treatment disorders at 1 institution underwent a retrospective evaluation to document infectious complications until death or end follow-up in October 2004. recipients allogeneic hematopoietic stem cell transplantation were compared with concurrent cohort also but did not receive alemtuzumab. Results. Twenty-seven identified (21 chronic lymphocytic leukemia and 6 plasma disorders). overall mortality was 37%, 7 10 deaths being related infection. Significant opportunistic infections occurred 9 (43%) leukemia, including cytomegalovirus, progressive multifocal leukoencephalopathy, adenovirus, toxoplasmosis, acanthamaebiasis. Thirty nonopportunistic 22 (82%) identified. 3 involved Enterococcus species bacteremia. When that transplantation, had incidence cytomegalovirus reactivation 66.7% (6 patients), 37% non-alemtuzumab group (10 27 patients; P = .15), post-transplant (excluding herpesviruses) 44.4% (compared 29.6% group; .41). Conclusions. Despite use herpesvirus Pneumocystis pneumonia prophylaxis, serious occur receiving Infectious are more varied diverse than has been reported trials date.